ArticleCureus2025
Novel Interleukin-11 Inhibitors Attenuate Collagen Production in Patient-Derived Synovial Fibroblasts.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeArthrofibrosis (AF), or excessive joint scarring, is a debilitating condition that causes pain and stiffness secondary to osteoarthritis and is often worsened by the surgical trauma of total knee arthroplasty (TKA). The underlying pathology involves dysregulated transforming growth factor-beta 1 (TGF-β1) signaling, which drives fibrogenesis. However, evidence from other organ systems suggests that interleukin-11 (IL-11) mediates fibrosis downstream of TGF-β1. This study examines the relationship between IL-11 and synovial fibrosis, a hallmark of AF, in patients with end-stage knee osteoarthritis (kOA) and evaluates the potential of novel small-molecule IL-11 inhibitors (NMX compounds) as a therapeutic option.
methodsSynovial fluid and tissue were collected from 24 patients undergoing TKA for kOA, who were divided into low (n = 12) and high (n = 12) fibrosis severity groups. Enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) and quantitative immunodetection were used to analyze IL-11 and TGF-β1 levels in synovial fluid and to relate them to histological fibrosis status. The effectiveness of NMX compounds (NM922, NM1157, and NM1332) was then tested on commercial synoviocytes and patient-derived fibroblastic synovial cells (FSCs) by measuring IL-11 and collagen type 1 (COL1) production before and during TGF-β1 stimulation in vitro. Parametric tests were employed to compare groups and evaluate associations.
resultsIL-11 and TGF-β1 levels in patient-derived synovial fluid were strongly correlated (R = 0.602; p = 0.003), and each was significantly linked to the severity of synovial fibrosis (R = 0.759; p = 0.0097 and R = 0.527; p < 0.0001, respectively). In vitro, NMX compound treatment reduced TGF-β1-induced IL-11 and COL1 by over 40% compared to untreated controls. Notably, patient-derived FSCs conserved a hyper-fibrotic phenotype, with baseline production of IL-11 and COL1 elevated by 182.86% and 139.63%, respectively, compared to commercial synoviocytes. In the pathologically primed FSCs, the lead compound NM1157 effectively countered fibrogenic stimulation, significantly reducing COL1 production by 44.5% (p = 0.0189) and IL-11 secretion by 28.4% (p = 0.0415).
conclusionsOur findings demonstrate a strong connection between IL-11 and synovial fibrosis status in patients with advanced kOA, indicating that IL-11 is a key mediator of this process. The ability of the new NMX compounds to significantly reduce fibrotic markers in patient-derived cells offers a promising preclinical basis for developing targeted therapies to prevent or treat AF attributable to kOA or other arthropathies and traumatic joint injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.